newsfilter
← Latest News
Business Wire·

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

- Late-Breaking Livdelzi (Seladelpar) Data Expand the Evidence Base in PBC, while Interim Data Show Durable, Consistent Results Across Key Markers - - Bulevirtide Data Strengthen Evidence of Efficacy and Safety Across